ô¼ö¼º ±ÙÀ§ÃàÁõ(SMA) Ä¡·á ½ÃÀå, ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2024-2032³â)
Spinal Muscular Atrophy Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
»óǰÄÚµå : 1573863
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 211 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,679,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,332,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,499,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ô¼ö¼º ±ÙÀ§ÃàÁõ(SMA) Ä¡·á ½ÃÀåÀº 73¾ï ´Þ·¯ ±Ô¸ð·Î 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 19.1%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â ½Å»ý¾Æ °ËÁø ÇÁ·Î±×·¥ÀÇ È®´ë·Î Á¶±â Áø´Ü°ú Ä¡·á Àû°Ý¼º Çâ»óÀ¸·Î À̾îÁö´Â ½Å»ý¾Æ °ËÁø ÇÁ·Î±×·¥ÀÇ È®´ë°¡ ²ÅÈü´Ï´Ù. Health Union, LLCÀÇ º¸°í¿¡ µû¸£¸é SMA´Â Àü ¼¼°è ½Å»ý¾Æ 6,000-10,000¸í´ç 1¸í²Ã·Î ¹ßº´Çϸç, 1Çü SMA°¡ °¡Àå ½É°¢Çϰí Àüü »ç·ÊÀÇ Àý¹Ý ÀÌ»óÀ» Â÷ÁöÇÕ´Ï´Ù. ÇöÀç ¾à 25,000¸íÀÇ ¹Ì±¹ÀÎÀÌ SMA¸¦ ¾Î°í ÀÖ½À´Ï´Ù. Áø´Ü ±â¼úÀÇ ¹ßÀü°ú ÀÇ·áÁø°ú ȯÀÚÀÇ ÀÎ½Ä °³¼±ÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è SMA Ä¡·á ½ÃÀåÀº À¯Çüº°·Î À¯¾Æ SMA, Werdnig-Hoffmannº´, ¼ºÀÎ SMA, Kugelberg-Welanderº´À¸·Î ±¸ºÐµÇ¸ç, Werdnig-Hoffmannº´ ºÐ¾ß´Â 2023³â 29¾ï ´Þ·¯·Î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ½Å»ý¾Æ °ËÁø Àǹ«È­·Î Á¶±â ¹ß°ßÀÌ ¿ëÀÌÇØÁ® ¿îµ¿ ´º·±ÀÌ ½É°¢ÇÏ°Ô ¼Õ½ÇµÇ±â Àü¿¡ °¡Àå È¿°úÀûÀÎ Ä¡·á¸¦ ½Å¼ÓÇÏ°Ô ½ÃÇàÇÒ ¼ö ÀÖ°Ô µÆ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¬±¸ °³¹ßÀº Ä¡·áºñ Àý°¨À» À§ÇÑ Á¦¾à»ç¿ÍÀÇ Á¦ÈÞ¿Í ÇÔ²² ȯÀÚ Á¢±Ù¼ºÀ» È®´ëÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖÀ¸¸ç, SMA1Çü Ä¡·á¸¦ À§ÇÑ Á¶±â Á¢±Ù ÇÁ·Î±×·¥ ¹× ÄÄÆÐ´Ï¾ð »ç¿ë ÇÁ·Î±×·¥µµ ½ÃÀå ¼ºÀåÀÇ ¸ð¸àÅÒÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

Ä¡·á À¯Çüº°·Î´Â ¾à¹°¿ä¹ý, ÁöÁö¿ä¹ý, ô¼ö ¼ö¼úÀÌ ÀÖ½À´Ï´Ù. ¾ÈƼ¼¾½º ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå, À¯ÀüÀÚ Ä¡·á ¹× ±âŸ ¾à¹°À» Æ÷ÇÔÇÑ ¾à¹° Ä¡·á ºÐ¾ß´Â 2023³â 64.2%ÀÇ Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, Spinraza(Nusinersen)¿Í Evrysdi(Risdiplam)¿Í °°Àº Çõ½ÅÀûÀÎ Ä¡·áÁ¦´Â À¯ÀüÀû ±Ù¿øÀ» Ç¥ÀûÀ¸·Î »ï°í SMN ´Ü¹éÁú »ý»êÀ» °­È­ÇÔÀ¸·Î½á SMA Ä¡·áÀÇ ÆÇµµ¸¦ ¹Ù²Ù¸ç ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÁÖ»çÁ¦¿Í °æ±¸¿ë ¾à¹°ÀÌ ¸ðµÎ Ãâ½ÃµÇ¸é¼­ Ä¡·á Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ´Ù¾çÇÑ È¯ÀÚµéÀÇ ´ÏÁî¿Í ¼±È£µµ¸¦ ÃæÁ·½Ãų ¼ö ÀÖ°Ô µÇ¾î ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì, ƯÈ÷ ¹Ì±¹Àº 2023³â Àü ¼¼°è SMA Ä¡·á ½ÃÀå¿¡¼­ 45.6%ÀÇ Å« Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ÇâÈÄ¿¡µµ ±× ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. Èñ±ÍÁúȯ¿¡ ´ëÇÑ Áö¿ø Á¤Ã¥, ÷´Ü ÀÇ·á ½Ã¼³, ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇèÀÌ ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä Á¦¾à»çÀÇ Á¸Àç¿Í R&D ÀÚ±ÝÀÇ Áõ°¡´Â ½ÃÀåÀ» ´õ¿í °­È­½Ã۰í ÀÖ½À´Ï´Ù. ô¼ö¼º ±ÙÀ§ÃàÁõ¿¡ ´ëÇÑ ÀÎ½Ä °³¼±°ú Á¶±â Áø´Üµµ Ä¡·á ȯ°æ È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï »óȲ

Á¦5Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : À¯Çüº°, 2021-2032³â

Á¦6Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Ä¡·á À¯Çüº°, 2021-2032³â

Á¦7Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Åõ¿© °æ·Îº°, 2021-2032³â

Á¦8Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2032³â

Á¦9Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Áö¿ªº°, 2021-2032³â

Á¦10Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Spinal Muscular Atrophy (SMA) Treatments Market was valued at USD 7.3 billion and is projected to grow at a CAGR of 19.1% from 2024-2032. Key drivers include the expansion of newborn screening programs, leading to earlier diagnoses and increased treatment eligibility. Early diagnosis enhances patient outcomes and boosts demand for neurological medications. Health Union, LLC reports that SMA affects 1 in every 6,000 to 10,000 newborns globally, with Type 1 SMA being the most severe and accounting for over half of all cases. Approximately 25,000 Americans currently live with SMA. Advancements in diagnostic technologies and increased awareness among healthcare providers and patients are anticipated to drive market growth.

The overall spinal muscular atrophy treatment industry is classified based on type, treatment type, route of administration, and region.

The global SMA treatment market is segmented by type into infant SMA, Werdnig-Hoffmann disease, adult SMA, and Kugelberg-Welander disease. The Werdnig-Hoffmann disease segment led the market with USD 2.9 billion in 2023. Mandatory newborn screenings have facilitated earlier detections, enabling prompt treatments that are most effective before significant motor neuron loss. This trend is set to drive market growth. Research and development, along with pharmaceutical collaborations to reduce treatment costs, have broadened patient access, further energizing market growth. Early access or compassionate use programs for SMA Type 1 treatment also bolster market momentum.

By treatment type, the market includes medication, supportive care, and spinal surgery. The medication segment, which includes antisense oligonucleotides, gene therapy, and other drugs, dominated with a 64.2% share in 2023. Innovative drugs like Spinraza (Nusinersen) and Evrysdi (Risdiplam) have transformed SMA treatment by targeting the genetic root and enhancing SMN protein production, driving market growth. The availability of both injectable and oral formulations has increased treatment accessibility, catering to diverse patient needs and preferences, thus fueling market growth.

North America, particularly the U.S., captured a significant 45.6% share of the global SMA treatment market in 2023 and is expected to maintain its dominance. Supportive policies for rare diseases, advanced healthcare facilities, and ongoing clinical trials are key factors driving market growth in the region. Additionally, the presence of leading pharmaceutical companies and increased funding for research and development are further bolstering the market. Rising awareness and early diagnosis of spinal muscular atrophy are also contributing to the expanding treatment landscape.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

Chapter 10 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â